Fundraising FoxMonopar Therapeutics
NASDAQ: MNPRLake Forest, US · Founded 2014 · Delaware corporation · 4 known investors
Find your way into Monopar Therapeutics
Sign up to see every warm intro you have to Monopar Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Monopar Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceutical candidates targeting advanced solid tumors (MNPR-101-Zr for imaging, MNPR-101-Lu and MNPR-101-Ac for therapy) and the late-stage Wilson Disease drug ALXN1840.
Founders & leadership
Monopar Therapeutics was founded in 2014 by Chandler D. Robinson.
Board
MJ
Michael J. BrownBoard director
Investors · 4
RA CapitalreportedBoston
How we know: stocktitan.net · Not right? Tell us
Also in the syndicate · 2
Adage Capital Partners LPADAR1 Capital Management
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 of 5 rounds · 2015–2024
▶$4.5MofferedAug 2017 · BiotechnologyRule 506(b)
▶$4.5MofferedAug 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chandler D. RobinsonExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Christopher M. StarrExecutive Officer, Director
- Michael J. BrownDirector
- Raymond W. AndersonDirector
- Offering amount
- $4.5M
- Minimum investment
- $120K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MofferedMar 2017 · BiotechnologyRule 506(b)
▶$10MofferedMar 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M. StarrExecutive Officer, Director
- Michael J. BrownDirector
- Chandler D. RobinsonExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Offering amount
- $10M
- Minimum investment
- $120K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3MofferedMar 2016 · BiotechnologyRule 506(b)
▶$3MofferedMar 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. BrownDirector
- Chandler D. RobinsonExecutive Officer, Director
- Christopher M. StarrExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Offering amount
- $3M
- Minimum investment
- $250.2K
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.1MraisedJun 2015 · 8 investors · BiotechnologyRule 506(b)
▶$2.1MraisedJun 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chandler D. RobinsonExecutive Officer, Director, Promoter
- Christopher M. StarrExecutive Officer, Director
- Andrew P. MazarExecutive Officer, Director
- Michael J. BrownDirector
- Offering amount
- $6M
- Amount sold
- $2.1M
- Minimum investment
- $250K
- Proceeds to insiders
- $1.4M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$83.4Mvaluation at IPODec 2019 · $8.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Monopar Therapeutics.
In the news
Frequently asked questions
- What does Monopar Therapeutics do?
- Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceutical candidates targeting advanced solid tumors (MNPR-101-Zr for imaging, MNPR-101-Lu and MNPR-101-Ac for therapy) and the late-stage Wilson Disease drug ALXN1840.
- Who founded Monopar Therapeutics?
- Monopar Therapeutics was founded by Chandler D. Robinson in 2014.
- Who are Monopar Therapeutics's investors?
- Monopar Therapeutics's investors include Janus Henderson Investors, RA Capital.
- How much funding has Monopar Therapeutics raised?
- Monopar Therapeutics has disclosed $2.1M raised across 1 of its 5 known rounds.
- Where is Monopar Therapeutics headquartered?
- Monopar Therapeutics is headquartered in Lake Forest, US.